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DOI 10.1186/s12890-015-0030-2RESEARCH ARTICLE Open AccessHIV associated Lymphocytic Interstitial Pneumonia:
a clinical, histological and radiographic study from
an HIV endemic resource-poor setting
Richard N van Zyl-Smit1†, Jashira Naidoo1†, Helen Wainwright2, Quanita Said-Hartley3, Malika Davids1,
Hillel Goodman3, Sean Rogers4 and Keertan Dheda1,5*Abstract
Background: There is a paucity of clinical and histopathological data about HIV-associated lymphocytic interstitial
pneumonitis (LIP) in adults from HIV endemic settings. The role of Ebstein-Barr virus (EBV) in the pathogenesis
remains unclear.
Methods: We reviewed the clinical, radiographic and histopathological features of suspected adult LIP cases at the
Groote Schuur Hospital, Cape Town South Africa, over a 6 year period. Archived tissue sections were stained for
CD3, CD4, CD8, CD20 and LMP-1 antigen (an EBV marker).
Results: 42 cases of suspected LIP(100% HIV-infected) were identified. 75% of patients were empirically treated for TB
prior to being referred to the chest service for further investigation. Tissue samples were obtained using trans-bronchial
biopsy. 13/42 were classified as definite LIP (lymphocytic infiltrate with no alternative diagnosis), 19/42 probable LIP
(lymphocytic infiltrate but evidence of anthracosis or fibrosis) and 10 as non-LIP (alternative histological diagnosis).
Those with definite LIP were predominantly young females (85%) with a median CD4 count of 194 (IQR 119–359).
Clinical or radiological features had poor predictive value for LIP. Histologically, the lymphocytic infiltrate comprised
mainly B cells and CD8 T cells. The frequency of positive EBV LMP-1 antigen staining was similar in definite and
non- LIP patients [(2/13 (15%) vs. 3/10 (30%); p = 0.52].
Conclusions: In a HIV endemic setting adult HIV-associated LIP occurs predominantly in young women. The diagnosis
can often be made on transbronchial biopsy and is characterized by a predominant CD8 T cell infiltrate. No association
with EBV antigen was found.
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Lymphocytic interstitial pneumonia (LIP) is an uncom-
mon histopathologic entity characterized by infiltration
of the interstitium and alveolar spaces of the lung by
lymphocytes, plasma cells, and other lymphoreticular
elements [1]. It was initially described in 1966, prior to
the HIV era, by Carrington and Liebow [2] and remains* Correspondence: keertan.dheda@uct.ac.za
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unless otherwise stated.a rare form of interstitial lung disease in HIV uninfected
adults [3]. With the global spread of HIV, LIP has be-
come a more common particularly in HIV endemic
countries. However, there are hardly any data about the
clinical and histological characteristics of HIV-associated
LIP in adults [4,5], and particularly those from HIV en-
demic countries.
Although the aetiology of LIP remains unclear an as-
sociation with several autoimmune disorders including
Sjogrens syndrome, systemic lupus erythematous (SLE),
rheumatoid arthritis and pernicious anaemia is well rec-
ognized [3]. In HIV-associated LIP a possible etiological
factor includes HIV-induced proliferation of bronchus-
associated lymphoid tissue BALT [6,7]. An alternativentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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in the pathogenesis of LIP in HIV uninfected persons [8].
However, this hypothesis has not been investigated in the
context of HIV-associated LIP.
The clinical (non-productive cough, progressive dys-
pnoea, and crackles) [1,5,9,10] and radiological features
(ground-glass appearance, centrilobular nodules, and
interstitial thickening) of LIP, using both chest x-ray and
CT, are non-specific [11-14]. Thus, open lung biopsy is
often required to clarify the diagnosis and to exclude
other possibilities including TB, which may often present
with similar features. However, open lung biopsy is often
unavailable or inaccessible in resource poor settings. The
role and utility of bronchoscopy and transbronchial biopsy
as an alternative diagnostic approach remains unclear.
Thus, there remains a paucity of data on HIV-
associated LIP from high burden settings to guide clin-
ical practice, and very little is known about the optimal
diagnostic approach, clinical outcomes, and histological
appearance of HIV-associated LIP. We therefore retro-
spectively reviewed the clinical, radiological, and histo-
pathological features of all cases of suspected LIP seen at
our institution, a tertiary referral centre, in Cape Town,
South Africa, over a 6-year period. We further inter-
rogated tissue sections to determine whether EBV
co-infection may have a role in the pathogenesis of
HIV-associated LIP.
Methods
The study was conducted in adults only, at the E16
Respiratory Clinic at Groote Schuur Hospital in Cape
Town, South Africa, which maintains a comprehensive
database of all bronchoscopic procedures and patient
diagnoses. Study approval was obtained from the Uni-
versity of Cape Town Health Sciences Faculty Research
Ethics Committee. Written informed consent was not
obtained as the study was a retrospective chart and case
review only.
Case identification
All clinical bronchoscopy case records were reviewed
over a 6-year period from 2003 to 2008. In parallel, and
to minimize ascertainment bias, all cases of LIP reported
by the Department of Pathology from the Groote Schuur
Hospital were identified. Thus, a total of 1325 pathology
codes covering all lung pathological diagnoses were
reviewed for the same time period to identify additional
cases not identified from the respiratory service records.
All case records where LIP was considered in the differ-
ential diagnosis were extracted for review (see Figure 1
for a study overview). Only HIV-infected patients and
cases where a tissue biopsy was available to ascertain the
cause of the underlying lung disease were finally in-
cluded in the analysis.Data collection and review
Patient demographics, clinical history, presenting signs
and symptoms and lung function testing data (basic
spirometry where available) were extracted from the
clinical notes. Two senior thoracic radiologists inde-
pendently reviewed radiological studies including chest
X-ray and CT scans. (HG, QS) Radiological features
were classified into several pre-specified categories:
reticular/nodular pattern, presence of ground glass or
alveolar infiltrate, pleural effusions and lymphadenop-
athy. Discordance was resolved by a third reader (senior
pulmonologist).
The classification of LIP disease was made on hist-
ology by an independent senior pulmonary pathologist
(HW) who was blinded to all clinical information. The
histological definition of LIP used for disease classifica-
tion was the presence of: expanded/thickened alveolar
walls by large number of small lymphocytes & plasma
cells (not in alveolar spaces) most marked around
broncho-vascular spaces and around vessels/lymphatics,
and frequent lymphoid follicles in the absence of an al-
ternative disease process associated with a lymphocytic
infiltrate. A diagnosis of probable LIP was made where
the lymphoid infiltrate was accompanied by second
process such as anthracosis or fibrosis. Thus, the diagnosis
of LIP was likely but the presence of a confounding
disease process could not be excluded with certainty.
Additionally, the specimen was considered adequate
and sufficient tissue present if it contained a bronchi-
ole (to evaluate follicular hyperplasia) and adequate
surrounding lung parenchyma. A diagnosis of non-LIP
was made where clear cut features of alternative disease
process was present. Additional immune-histochemical
staining was performed using antibodies for CD4 (Clone
4B12 Leika), CD8 (Clone NCL-CD8-4B11 Leika), CD20
(Clone L26 Dako) and EBV – LMP-1 Antigen (Clone
CS.1-4 Dako).
Statistical analysis
Categorical variables were compared using the χ2 test
and continuous variables were compared using Student’s
t-test where appropriate. The Mann–Whitney test was
used for comparison of non-parametrically distributed
continuous variables. (Graphpad Prism, Version 5.03 and
Open Epi, Version 2.3.1 were used).
Results
Case identification
A total of 3460 clinical bronchoscopy case records
were reviewed and 33 possible LIP cases were identi-
fied (see Figure 1 for study overview). A further 13
potential cases were identified from the pathological
biopsy records. Of the 46 potential cases identified, 4
were excluded (Figure 1).
Figure 1 Study overview.
van Zyl-Smit et al. BMC Pulmonary Medicine  (2015) 15:38 Page 3 of 7Patient classification and demographic features
Of the 42 patients available for evaluation, 13 were classi-
fied as definite LIP (lymphocytic infiltrate with no alterna-
tive diagnosis), 19 probable LIP (lymphocytic infiltrate but
evidence of anthracosis or fibrosis) and 10 as non-LIP
(alternative histological diagnosis). All participants were
HIV-infected, and only one patient with LIP was on anti
retroviral therapy at time of diagnosis. The LIP patients
were predominantly female 85%(11/13), young (median
age of 34 years) with severe immunosuppression (median
CD4 count 194 cells/ml); see Table 1 for details and
p values.
Clinical features
The predominant symptom was cough 90% (10/11) which
was productive in 64% (7/11) of participants. The median
duration of symptoms was 5 months (range 1–84) with
class II or III dyspnea occurring in 70%(9/13) of patients.
Notably, the most common referring diagnosis in those
confirmed to have LIP (77%) was non-resolving tubercu-
losis. Clinical features were varied with a normal chest
examination in a third of LIP patients. No participants with
LIP had digital clubbing. There were no clinical features
that distinguished LIP from the non-LIP group (Table 1).
Lung function
Lung function tests were only available for 8/13 definite
LIP patients. Reduced volumes (restrictive lung function)were evident for most participants with LIP (6/8); median
percentage predicted FVC was 77% (range 60–103), FEV1
64% (52–100), and FEV1/FVC ratio 87% (range 77–97).
None of the 8 definite LIP patients had obstructive lung
disease. The lung function abnormalities in the probable
LIP group were similar to the LIP group (Figure 2).
Radiology
38 participants had chest x-rays and 14 had CT scans
available for evaluation (see Table 2). No chest x-rays
were considered normal in the LIP group. Almost half
(42%) of the participants had a reticular or reticular
nodular infiltrate. Hilar lymphadenopathy was present in
50% (6/12). Pleural effusions were noted in 2 partici-
pants. There were no distinguishing chest x-ray features
between the diagnostic groups. Six CT scans were
available for analysis in the definite LIP group. Two
demonstrated a ground glass pattern and 3 had nodu-
lar infiltrates. No interlobular septal thickening, bron-
chiectasis, thickened bronchovascular bundles, lymph
nodes or pleural effusions were seen in the definite LIP
group and only 1 patient had lung cysts.
Histological diagnosis
Of the 46 cases reviewed 4 were excluded as two were
found to be from HIV negative participants and a fur-
ther 2 had insufficient tissue to perform the additional
stains. 13 cases met the case definition of LIP with 19
Table 1 Clinical characteristics of patients with suspected LIP
Definite LIP Non-LIP Probable LIP Definite & probable LIP P value
n = 13 n = 10 n = 19 n = 32
Demographic characteristics
Age median (range) 34 (21–57)* 42 (26–66)* 39(20–52) 35 (20–57) *p = 0.11
Gender: Female n (%) 11(85%)* 3 (30%)*# 15 (79%) 20 (77%)# *p = 0.006
#p = 0.008
CD4 count median (range) 194 (104–464)* 157(51–323)* 216 (30–444) 216 (30–464) p = 0.18
Number of participants on ARV at presentation 1/11 (9%) 5/8 (62.5%)* 8/13 (61.5%) 9/24(37.5%)* *p = 0.25
Symptoms
Duration in months Median (range) 5 (1–84) 4 (.75-12) 6 (0.5-24) 6 (0.5-84) p = 0.45
Presence of cough 10/11 (90%) 10/10 (100%) 16/18 (88%) 26/29(89.7%)
Productive cough 7/11 (64%)* 6/10(60%)* 12/16 (75%) 19/27 (71%) *p = 0.43
Dyspnea (NHYA)
Class 1 3 (25%) 2 (20%) 6 (33%) 9 (30%)
Class 2 8 (67%) 4 (40%) 9 (50%) 17 (57%)
Class 3 1(3%) 3 (30%) 3 (17%) 4 (13%)
Class 4 0 1 (10%) 0(0%) 0
Referral diagnosis of non-resolving TB 77% 70% 86%
Examination findings
BMI kg/cm2 mean (SD) 25.3(5.3) 23.8(6.2) 23.9(5.4) 24.6(5.2) p = 0.94
Presence of clubbing 0/ 11 (0%) 3/10 (30%) 6/18(33%) 6/29 (20%)
Auscultation
Normal 4 (33%) 2 (20%) 7 (39%) 11 (38%)
Bibasilar crackles 7 (58%) 6 (60%) 9 (50%) 16 (55%)
Diffuse crackles 0 1(10%) 2 (11%) 2 (7%)
Wheeze 0 0 0 0
Bronchial breathing 1 (8%) 1(10%) 0 0
*,#p value for comparison between groups indicated.
Figure 2 Lung function abnormalities in patients with LIP. Individual patient values are depicted with Mean and SEM. Significant comparisons are
as indicated with p values. FVC percentage predicted is depicted on left axis. FEV1/FVC ratio is depicted on the right axis. LIP(Lymphocytic
interstitial pneumonia). Horizontal dotted lines indicated normal cut off values.
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Table 2 Radiological findings based on chest x-rays available from 38 patients
Definite LIP Non-LIP Probable LIP Definite & probable LIP P value
N = 12 N = 8 18 30
Dominant CXR pattern
Normal 0 0 1 (6%) 1 (3%)
Reticular/reticulo-nodular 5 (42%) 4 (50%) 9 (50%) 14 (47%)
Alveolar 4 (33%) 1 (13%) 1 (11%) 5 (17%)
Ground Glass 3 (25%) 3 (38%) 7 (44%) 10 (33%)
Pleural Effusion 2 (17%) 0 2 (11%) 4 (13%)
Lymphadenopathy 6 (50%)* 2 (25%)* 5 (28%) 11 (37%) *p = 0.15
*p value for comparison between groups indicated.
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pathology.
Using additional staining for B cell and T cell markers,
the cellular predominance was shown to be of CD8 cell
origin. There were also high numbers of CD20 positive
B cells and high CD8 to CD4 ratio (Figure 3). Only 2 pa-
tients with definite LIP had EBV positive biopsies. There
was no difference in the frequency of EBV positive stain-
ing between the LIP (15%) and the non-LIP (30%) group
(p = 0.52), data not shown.
Discussion
There are virtually no data about HIV-associated LIP
from HIV endemic settings. Our data suggest that
HIV-associated LIP although still an uncommon diag-
nosis in high HIV burden settings, is frequently mis-
diagnosed as TB. Clinical and radiological presentationFigure 3 Immunomarkers for B and T cells in patients with confirmed LIP
Median and Interquartile range. Comparisons between LIP and Non LIP areis non-specific. The diagnosis, however, can be made
with adequate transbronchial biopsies rather than
resorting to open lung biopsy and the cellular pheno-
type is that of CD8 and CD20 predominance. In this
preliminary study the LMP-1 EBV antigen does not
appear to be important in the pathogenesis of HIV-
associated LIP.
It is striking that 75% of patients were initially treated
for TB, which reflects the high burden of TB in South
Africa [15]. Furthermore the lack of access to diagnostic
tools to exclude alternative diagnoses makes empiric
therapy a common practice [16]. Thus, in a high TB/
HIV burden settings, the symptoms and CXR features of
LIP are frequently attributed to TB and the diagnosis is
generally missed unless a high index of suspicion and
adequate follow up of patients is maintained. Even with
the advent of Gene Xpert MTB/RIF testing now beingcompared to non- LIP patients. Individual patient data is depicted with
depicted with p values.
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patients with advanced HIV will most likely be treated
for TB prior to referral to a tertiary level service for a
bronchoscopy [15,17].
The demographic characteristics and clinical features
of this HIV-associated LIP cohort of patients is similar
to that described in the literature: the preponderance of
young females has been described previously [1,3,13]
although it has been also been described in white men
[18]. The prevalence of HIV in South Africa is highest
amongst black African women and thus may be reflected
in the demographics of our population sample. HIV-
associated LIP is generally not associated with advanced
HIV in most published studies and case reports where
CD4 counts are generally reported to be in the normal
range [18-20]. In our cohort, although the median CD4
count was 194, several participants had CD4 counts over
300. In this cohort, and not dissimilar to other reports
[9], a wide duration of symptoms prior to diagnosis was
recorded; the median duration of symptoms of 5 months
suggests that an acute presentation is not common.
Symptoms and examination findings are also generally
non-specific, with cough and dyspnea being the hall-
mark, as previously reported in the HIV uninfected per-
sons with LIP [1,3].
In keeping with other literature, lung function tests
showed a restrictive pattern [13]. Unfortunately as these
participants were being investigated for infectious lung
diseases, full lung volumes and diffusing capacity was
not measured. The radiographic features were predomin-
antly of an interstitial pattern with associated lymphaden-
opathy. In contrast to the published literature, pleural
effusions occurred in roughly 15% of participants. CT
scans did not show any predominant pattern that could
potentially assist with the diagnosis.
There were several insights from the histopathological
analysis. Although CD8 preponderance has been well
described in LIP the type of CD4 versus CD8 infiltration
in the context of HIV-associated LIP has not been well
studied nor described. In addition we evaluated the pos-
sible role of EBV in the pathogenesis of HIV-associated
LIP. Several pathogenic mechanisms have been described
including autoimmunity, HIV-associated lymphocytosis,
dysfunctional regression of an immunological response to
antigen in the lung, and viral infections including EBV
[3,4]. Data on EBV have been discordant [21-23]. EBV
latent membrane protein 1 is an attractive hypothesis as it
up-regulates bcl-2, which has been shown to confer a sur-
vival advantage for lymphocytes in other lymphoprolifera-
tive disorders, and thus could enhance tissue lymphocyte
accumulation and survival in LIP. However, in contradis-
tinction to Barbera et al. who detected EBV in the open-
lung biopsy specimens of 9 of 14 patients with LIP [24]
and another study that detected EBV DNA in 80% of lungspecimens from HIV-positive children with LIP [21], we
failed to detect any difference in EBV frequency using an
LMP-1 immunoassay.
This study has several limitations. The small number
of subjects and retrospective design lends itself to as-
certainment bias; however, we did compare LIP to par-
ticipants with non-LIP. There were also missing data.
However, we do show that it is possible to make the
diagnosis using transbronchial biopsy and have con-
firmed the CD8 predominant nature of infiltrates in
HIV-infected persons. We did not evaluate other EBV-
associated antigens or use PCR however the lack of
detectable antigen in most biopsies makes EBV an
unlikely culprit driving pathogenesis in the African
setting, and presence of DNA may often constitute an
epiphenomenon rather than causality.
Conclusion
In conclusion, although HIV-associated LIP remains an
uncommon condition, even in HIV-endemic settings,
the diagnosis can often be made via bronchoscopy and
transbronchial biopsy. The disease occurs in Africa
predominantly in young women with moderate to se-
vere immunosuppression. The histological features are
typically of a CD8 and CD20 infiltrate and EBV does
not appear to be a major pathogenic feature in this
adult population.
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